IMVT

Immunovant Inc

IMVT.US immunovant.com + Research + Basket
CIK 0001764013
Employees 315
Phone 917 410 3120
Fiscal year end March
IPO Jun 21, 2019
Address 1000 Park Forty Plaza, Durham, NC, United States, 27713
29.64
+0.22 (+0.75%)
USD · NASDAQ
52-week range
21.43
45.42
Trading at 34% of the 52-week range
Market Cap
6.08B
P/E Ratio
0.00
Forward P/E
0.00
Book Value
3.57
Div. Yield
N/A
% Institutions
54.74%
% Insiders
56.01%

1 Year

+36.9%

3 Year

-10.0%

10 Year

+197.9%
Description

Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Actions

Add an action for IMVT.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Dr. Frank M. Torti M.B.A., M.D. Executive Chairperson of the Board 1979
Dr. Eric Venker M.D., Pharm.D. CEO & Director 1987
Mr. Tiago M. Girao CPA Chief Financial Officer 1979
Ms. Melanie Gloria B.S.N. Chief Operating Officer 1978
Dr. Jay S. Stout M.S., Ph.D. Chief Technology Officer 1963
Mr. Christopher A. Van Tuyl Esq., J.D. Chief Legal Officer & Corporate Secretary 1975
Ms. Christine Blodgett Senior Vice President of Human Resources NA
Ms. Becky Merlina Senior VP & Global Head of Quality NA
Ms. Yan Zheng M.S., Ph.D. Senior Vice President of Biostatistics, Programming & Data Management NA
Ms. Sheetal Patel M.B.A., M.D., M.S. Senior Vice President of Clinical Development NA

Insider Trading

Open insider trading
Date Insider Name Title Transaction Type Shares Price Value SEC
Apr 23, 2026 Tiago Girao N/A Sale 25.76K $29.62 $763.01K SEC
Apr 23, 2026 Jay S Stout N/A Sale 2.75K $29.62 $81.57K SEC
Apr 08, 2026 Jay S Stout N/A Sale 10.13K $24.83 $251.58K SEC
Apr 08, 2026 Melanie Gloria N/A Sale 8.72K $24.83 $216.57K SEC
Apr 08, 2026 Tuyl Christopher Van N/A Sale 5.17K $24.83 $128.25K SEC
Apr 02, 2026 Eric Venker N/A Sale 14.23K $24.10 $342.92K SEC
Mar 18, 2026 Tuyl Christopher Van N/A Sale 2.88K $24.97 $71.84K SEC
Jan 21, 2026 Jay S Stout N/A Sale 1.98K $26.03 $51.46K SEC
Jan 07, 2026 Jay S Stout N/A Sale 1.20K $26.53 $31.92K SEC
Dec 18, 2025 Tuyl Christopher Van N/A Sale 10.81K $26.91 $290.98K SEC
Dec 01, 2025 Andrew J Fromkin N/A Sale 22.25K $23.25 $517.29K SEC
Dec 01, 2025 Douglas J Hughes N/A Sale 15.00K $23.24 $348.60K SEC
Nov 20, 2025 Melanie Gloria N/A Sale 12.63K $23.62 $298.23K SEC
Oct 22, 2025 Jay S Stout N/A Sale 2.52K $19.03 $47.96K SEC
Oct 22, 2025 Michael Geffner N/A Sale 2.60K $19.03 $49.38K SEC
Oct 08, 2025 Jay S Stout N/A Sale 1.59K $16.30 $25.84K SEC
Oct 08, 2025 Michael Geffner N/A Sale 1.27K $16.30 $20.73K SEC
Jul 23, 2025 Jay S Stout N/A Sale 2.81K $18.15 $50.91K SEC
Jul 23, 2025 Michael Geffner N/A Sale 2.39K $18.15 $43.29K SEC
Jul 09, 2025 Jay S Stout N/A Sale 1.52K $17.24 $26.19K SEC

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
FMR Inc 16.19M Jun 30, 2026 7.84% $0.03 -4.49%
Deep Track Capital, LP 9.34M Jun 30, 2026 4.52% $5.24 -18.96%
BlackRock Inc 7.18M Jun 30, 2026 3.48% $0.00 9.22%
Farallon Capital Management, L.L.C. 5.81M Jun 30, 2026 2.81% $1.03 275.49%
Baker Bros Advisors LP 5.44M Jun 30, 2026 2.63% $1.05 -0.42%
State Street Corp 4.62M Jun 30, 2026 2.24% $0.01 1.74%
Morgan Stanley - Brokerage Accounts 4.53M Jun 30, 2026 2.20% $0.01 16.97%
TCG Crossover Management, LLC 4.46M Jun 30, 2026 2.16% $4.13 0.00%
Vanguard Portfolio Management, LLC 3.91M Jun 30, 2026 1.89% $0.01 5.55%
Vanguard Capital Management, LLC 3.64M Jun 30, 2026 1.76% $0.00 0.51%
Jennison Associates LLC 3.31M Jun 30, 2026 1.60% $0.08 3.55%
Two Seas Capital LP 3.20M Mar 31, 2026 1.55% $1.11 11.68%
RTW INVESTMENTS, LLC 3.18M Jun 30, 2026 1.54% $1.05 0.00%
ADAR1 Capital Management LLC 2.33M Jun 30, 2026 1.13% $4.11 -13.00%
Geode Capital Management, LLC 2.23M Jun 30, 2026 1.08% $0.00 6.81%
T. Rowe Price Investment Management,Inc. 2.22M Jun 30, 2026 1.08% $0.06 -38.49%
Woodline Partners LP 1.98M Jun 30, 2026 0.96% $0.24 0.00%
T. Rowe Price Associates, Inc. 1.83M Jun 30, 2026 0.89% $0.01 438.63%
The Goldman Sachs Group Inc 1.75M Jun 30, 2026 0.85% $0.01 -1.90%
Armistice Capital, LLC 1.74M Jun 30, 2026 0.84% $0.82 -51.30%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Fidelity Growth Company Fund 5.09M 2.47% ▲ 0.00% Aug 31, 2026
2 Vanguard MStar Total Stk Mkt Idx Invest 3.02M 1.46% ▲ 15.66% Sep 30, 2026
3 iShares Russell 2000 ETF 2.25M 1.09% ▼ 0.48% Sep 30, 2026
4 State Street® SPDR® S&P® Biotech ETF 2.12M 1.03% ▼ 1.88% Sep 30, 2026
5 Vanguard Small Cap Index 2.09M 1.01% ▲ 10.86% Sep 30, 2026
6 Fidelity Growth Company K6 1.41M 0.68% ▲ 0.00% Aug 31, 2026
7 Vanguard MStar Small Cap Growth Indx Inv 1.17M 0.56% ▲ 7.20% Sep 30, 2026
8 Fidelity Series Growth Company 1.09M 0.53% ▼ 0.23% Aug 31, 2026
9 Fidelity Small Cap Index 932.98K 0.45% ▲ 0.82% Jul 31, 2026
10 iShares Russell 2000 Growth ETF 808.39K 0.39% ▼ 0.13% Sep 30, 2026

Financial Highlights

▼
Market Cap: $6.08B
EBITDA: $-565.61M
Book Value: $3.57
Earnings/Share: $-2.82
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -46.73%
ROE (TTM): -80.10%
Revenue (TTM): $0.00
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 0.00%

Valuation Metrics

Enterprise Value: $5.06B
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 206.55M
Shares Float: 91.77M
% Insiders: 56.01%
% Institutions: 54.74%
Shares Short: 18.27M
Shares Short (Prior Month): 17.42M
Short Ratio: 10.91
Short % Float: 19.67%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$0.00
Cost of Goods Sold
adjust
$-409.00K
Gross Profit
subtotal
$-409.00K
SG&A
adjust
$-76.24M
R&D
adjust
$-456.66M
Operating Income
subtotal
$-532.90M
Other / Non-Operating Items
adjust
$27.30M
Net Income
subtotal
$-505.61M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about IMVT.US!